United Kingdom

Lexicon Pharmaceuticals Inc (LXRX.OQ)

LXRX.OQ on NASDAQ Stock Exchange Global Select Market

20 Feb 2018
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Lexicon Pharmaceuticals reports Q3 loss per share $0.29
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Lexicon Pharmaceuticals Inc :Lexicon Pharmaceuticals reports third quarter 2017 financial results and provides a business update.Q3 loss per share $0.29.Q3 revenue $26.9 million versus I/B/E/S view $27.7 million.Q3 earnings per share view $-0.37 -- Thomson Reuters I/B/E/S.  Full Article

Lexicon Pharmaceuticals agrees to buy remaining obligations to Symphony Icon
Wednesday, 5 Oct 2016 

Lexicon Pharmaceuticals Inc: Lexicon Pharmaceuticals announces agreement to buy out remaining obligations to Symphony Icon . Buyout payment may be payable in cash or a combination of cash and up to 50% in lexicon common stock, at Lexicon's option . Lexicon will make a single payment to Symphony Icon of $21.013 million .Buyout to replace, eliminate remaining contingent payments of up to $29.550 million for which co was obligated.  Full Article

Lexicon Pharmaceuticals Q2 loss per share $0.37
Thursday, 4 Aug 2016 

Lexicon Pharmaceuticals Inc : Q2 loss per share $0.37 . Q2 earnings per share view $-0.40 -- Thomson Reuters I/B/E/S . Q2 revenue view $12.4 million -- Thomson Reuters I/B/E/S .Q2 revenue $20.1 million versus $400,000.  Full Article

Lexicon announces FDA priority review of new drug application
Tuesday, 31 May 2016 

Lexicon Pharmaceuticals Inc : FDA has granted a priority review of NDA filing and set a PDUFA target action date of November 30, 2016 .Lexicon announces fda priority review of new drug application for Telotristat Etiprate for the treatment of carcinoid syndrome.  Full Article

BRIEF-Biopharma Credit Says Enetered Into Term Loan Agreement For Up To US$200 Mln With Lexicon Pharmaceuticals

* BIOPHARMA CREDIT PLC SAYS ENETERED INTO A DEFINITIVE TERM LOAN AGREEMENT FOR UP TO US$200 MILLION WITH LEXICON PHARMACEUTICALS, INC. Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)